Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in...

Area of Science:

• Molecular Biology
• Cancer Therapeutics
• Structural Biology

Background:

• The SF3B1 protein is essential for accurate RNA splicing and is frequently mutated in various cancers.
• Splicing modulators (SMs), like H3B-8800, are being investigated for cancer treatment, particularly for SF3B1-mutant cancers.
• H3B-8800 demonstrates preferential lethality in cancer cells with the K700E SF3B1 mutation, but its precise mechanism remains unclear.

Purpose of the Study:

• To elucidate the molecular mechanism behind H3B-8800's selective killing of cancer cells with SF3B1 mutations.
• To investigate the binding and dissociation dynamics of H3B-8800 with wild-type and K700E SF3B1 complexes.
• To identify potential druggable sites for future targeted therapies.

Main Methods:

• Microsecond-long all-atom molecular dynamics simulations were employed.
• The binding/dissociation mechanisms of H3B-8800 to wild-type and K700E SF3B1 complexes were analyzed at the atomic level.

Main Results:

• The K700E mutation in SF3B1 minimally impacts the thermodynamics and kinetics of H3B-8800 binding.
• The selectivity of H3B-8800 is not due to preferential binding to the K700E SF3B1 mutant.
• Both the K700E mutation and H3B-8800 binding alter SF3b complex dynamics, potentially affecting spliceosome interactions.
• A potential druggable pocket near the K700E mutation site was identified.

Conclusions:

• H3B-8800's selectivity for SF3B1-mutant cancer cells is not driven by direct preferential binding to the mutated protein.
• Altered SF3b dynamics, influenced by the mutation and drug binding, may underlie the observed cellular effects.
• The identified druggable pocket offers a new avenue for developing targeted therapies against SF3B1-mutant cancers.